Anti-HIV drug lenacapavir called 'breakthrough of the year ... - NPR
Dec 12, 2024 · But 2024 has fueled increasing optimism among leading infectious disease experts after the results of two groundbreaking clinical trial results for a drug called lenacapavir showed it to be...
New HIV drug can only offer hope of ending AIDS if all have …
Jul 10, 2024 · Twice-yearly injections of Lenacapavir showed overwhelming efficacy for preventing HIV infections compared to standard oral preventative HIV medicines, known as pre-exposure prophylaxis (PrEP). Additional trials are ongoing in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States.
Twice-yearly shot proves successful at preventing HIV infection ... - CNN
Jul 24, 2024 · Phase 3 trial data shows that a twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections. Two shots a year of a drug currently used to treat HIV...
Science’s 2024 Breakthrough of the Year: Opening the door to a
Dec 12, 2024 · Progress has stalled, leaving the world far from the goal set by the Joint United Nations Programme on HIV/AIDS (UNAIDS) of cutting new HIV infections to below 370,000 next year and less than 200,000 in 2030. But lenacapavir might break the impasse.
Lenacapavir Named 2024 Breakthrough of the Year: A New Era in HIV …
5 days ago · This innovative injectable drug, administered every six months, has demonstrated up to 99.9% efficacy in preventing HIV infections. Lenacapavir’s success represents a revolutionary step in global HIV prevention, particularly for high-risk populations, and brings new hope to millions worldwide.
Long-acting injectable lenacapavir continues to show promising …
Sep 26, 2024 · WHO welcomes the latest findings from the PURPOSE-2 trial on long-acting injectable lenacapavir (LEN) for HIV prevention. An interim analysis, announced on 12 September 2024, demonstrated the drug’s remarkable efficacy in preventing HIV.
Lenacapavir: The 'Breakthrough Of The Year' Drug For HIV Care - NDTV.com
Dec 30, 2024 · The details of the clinical trials study (called PUPOSE 2) conducted by Gilead state, "Lenacapavir was highly effective at reducing HIV infections among trial participants: 99.9% of participants ...
Islatravir plus lenacapavir could be the first once-weekly oral HIV ...
Mar 6, 2024 · A once-daily oral combination therapy for HIV — bictegravir plus lenacapavir — is more effective than complex regimens are, according to results from a phase 2 study of people with HIV who are virologically suppressed, presented the Conference on Retrovirus and Opportunistic Infections (CROI) in Denver.
Gileads Twice Yearly Lenacapavir Demonstrated 100 Efficacy and ...
Jun 20, 2024 · PURPOSE 1 met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily oral Truvada ® (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) and background HIV incidence (bHIV).
An injectable HIV-prevention drug is highly effective - NBC News
Thrilled over the news Thursday that lenacapavir was 89% more effective at preventing HIV than daily oral preventive medication among gay, bisexual and transgender people, plus previous...